![Xingfeng Bao](https://cdn.asp.events/CLIENT_HubXchan_638DBA0F_0C6E_8D3C_A444829FC0C4B73E/sites/HubXChange/media/libraries/experts/Xingfeng-Bao-VP-Head-of-Biology-GV20-Therapeutics.webp/fit-in/500x500/filters:no_upscale())
![](https://cdn.asp.events/CLIENT_HubXchan_638DBA0F_0C6E_8D3C_A444829FC0C4B73E/sites/HubXChange/media/libraries/experts/GV20-Therapeutics.jpg)
Xingfeng Bao
VP Head of Biology,
GV20 Therapeutics
Dr. Bao is currently VP, Head of Biology at GV20 Therapeutics, a clinical stage, AI and cancer genomics-driven oncology company. Prior to joining GV20, he was Executive Director, Head of Cancer Immunology and Pharmacology at H3biomedicine, where he led the company’s discovery and translational biology group focused on cancer immunotherapy and antibody-drug conjugates. In his earlier career, he has also held roles of increasing responsibilities at Eisai oncology business unit. Dr. Bao earned his doctorate in 2002 and completed his postdoctoral fellow at Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, California.
Sessions